E
Emily J. Hillmer
Researcher at University of Texas MD Anderson Cancer Center
Publications - 4
Citations - 402
Emily J. Hillmer is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Dosimeter & Loss function. The author has an hindex of 2, co-authored 3 publications receiving 250 citations.
Papers
More filters
Journal ArticleDOI
STAT3 signaling in immunity.
TL;DR: Information on the numerous and distinct biological actions of STAT3 is summarized, and recent discoveries are highlighted, with a specific focus on STAT3 function in the immune and hematopoietic systems.
Journal ArticleDOI
Genetic rescue of lineage-balanced blood cell production reveals a crucial role for STAT3 antiinflammatory activity in hematopoiesis.
Huiyuan Zhang,Haiyan S. Li,Emily J. Hillmer,Yang Zhao,Taylor T. Chrisikos,Taylor T. Chrisikos,Hongbo Hu,Xiao Wu,Erika Thompson,Karen Clise-Dwyer,Karen A. Millerchip,Yue Wei,Nahum Puebla-Osorio,Saakshi Kaushik,Margarida A. Santos,Bin Wang,Guillermo Garcia-Manero,Jing Wang,Shao Cong Sun,Shao Cong Sun,Stephanie S. Watowich +20 more
TL;DR: A crucial role is demonstrated for STAT3 antiinflammatory activity in preservation of HSPCs and lineage-balanced hematopoietic system, and this is mediated by STAT3-dependent restraint of excessive proinflammatory signaling via Ubc13 modulation.
Cytokine & Growth Factor Reviews
TL;DR: In this paper, the authors propose a method for measuring the performance of a single node in a set of images.ING and INDEXING, e.g., this paper.
ReportDOI
IER-538 CED4A Report: Godiva-IV Dosimetry Exercise 2022
A. Tamashiro,Devin Stone,L J Anspach,B. Champine,Mike Firpo,S. Uchiyama,P. Witter,P. Yap-Chiongco,C. Percher,David P. Heinrichs,Joetta Goda,Terence Grove,Theresa Cutler,Nicholas Thompson,Roberta F. Weldon,Lauren A. Overbay,T. Omoto,Milan S. Gadd,Emily J. Hillmer,D. Ward,John Kevin Kilbane,Dale T. Roberts,R Abbott,John Epps,David Vogt,H. Healy,S. Murphy,R. J. Ludwigsen,K. G. Veinot,KJ Mcmahon,A. H. Detweiler,Alexander Romanyukha,Derek Boozer,Keith Consani,Philip Angus,Nathan Y. Vessey,Kalvin P. Chapman,Gail McCabe,Ed Cornick,François Trompier,Y. Ristic,Jonas Herth,Sophie Pignet +42 more
TL;DR: The IER 538, the International Nuclear Accident Dosimeter (NAD) Intercomparison Exercise with Godiva-IV, was held in August of 2022 and tested participants' NADs and dosimetry personnel to the dose estimation requirements established by ANSI/HPS-N13.3 Dosimetry for Criticality Accidents and DOE-STD-1098-2017, Radiological Control as mentioned in this paper .